COVID-19 International Drug Pregnancy Registry
ConditionCovid19
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-50
SponsorPregistry
About this trial
The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (LMP) to end of pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.
Eligibility criteria
Qualifiers
Pregnant or recently pregnant (up to 30 days after the end of pregnancy) at time of enrollment
Age ≥18 years at time of enrollment
With mild to severe COVID-19 during pregnancy
Either
Disqualifiers
None
Trial design
Treatments tested in this trial
- Antiviral Agents
- Monoclonal antibody
Treatment groups
2,000 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov